12 Best Italian Stocks to Buy in 2025

Page 10 of 10

1) Genenta Science S.p.A. (NASDAQ:GNTA)

Number of Hedge Fund Holders: N/A

Average Upside Potential: ~425.6%

Genenta Science S.p.A. (NASDAQ:GNTA) is a clinical-stage biotechnology company, which is engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Also, it has its headquarters in Milan, Italy. Maxim Group analyst Jason McCarthy maintained a “Buy” rating on the company’s stock, setting a price target of $21.00. The analyst’s rating is backed by a combination of factors related to the promising developments of Genenta Science S.p.A. (NASDAQ:GNTA)’s gene therapy platform, Temferon. The approval of a Phase 1 trial for Temferon in metastatic renal cell cancer (mRCC) by the Agenzia Italiana del Farmaco aligns with European Medicines Agency standards and happens to be a significant milestone.

Temferon is expected to provide a new experimental treatment to patients with late-stage mRCC. Also, the insights gained from Genenta Science S.p.A. (NASDAQ:GNTA)’s uMGMT Glioblastoma Multiforme (TEM-GBM) studies continue to inform and enhance the understanding, demonstrating Temferon’s potential to reprogram the tumor microenvironment and activate the immune system throughout diverse oncology landscapes. In another significant development, the company announced that it has strengthened its partnership with AGC Biologics, which is a global contract development and manufacturing organization (CDMO), by amending the Development and Master Services Agreement.

Notably, this amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta Science S.p.A. (NASDAQ:GNTA)’s cell therapy product, ensuring compliance with cGMP standards. The move improves its production capabilities, potentially enhancing efficiency and reliability in the manufacturing processes.

While we acknowledge the potential of GNTA as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for a deeply undervalued AI stock that is more promising than GNTA  but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 10 of 10